Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Renewed interest exists in using prophylactic antibiotics to decrease exacerbations and enhance quality of life for chronic obstructive pulmonary disease (COPD) patients.
• Systematic reviews are essential for evaluating the efficacy and safety of such treatments.

Purpose of the Study:

• To assess the effectiveness of regular prophylactic antibiotic treatment in reducing exacerbations and improving quality of life in COPD patients.

Main Methods:

• A systematic review of randomized controlled trials (RCTs) comparing prophylactic antibiotics with placebo in COPD patients was conducted.
• Literature searches were performed using the Cochrane Airways Group Trials Register and relevant study bibliographies, with the latest search in August 2013.

Main Results:

• Seven RCTs (3170 participants) indicated that continuous prophylactic macrolide antibiotics significantly reduced exacerbations (OR 0.55; 95% CI 0.39 to 0.77) and improved quality of life (MD -1.78; 95% CI -2.95 to -0.61), though the quality of life improvement was below clinical significance.
• Pulsed antibiotic treatment showed a non-significant reduction in exacerbations and its impact remains uncertain.
• Adverse events included hearing loss with azithromycin and gastrointestinal issues with moxifloxacin, raising concerns about antibiotic resistance.

Conclusions:

• Continuous prophylactic macrolide antibiotics offer a clinically significant benefit in reducing COPD exacerbations.
• The efficacy of pulsed antibiotics is uncertain, and careful consideration of antibiotic resistance and adverse effects is necessary.
• Findings apply to frequent exacerbators, older individuals, and those requiring oxygen, necessitating a balance between individual benefits and societal harms of antibiotic overuse.